Vanishing platelets: Rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction

Texas Heart Institute Journal

Volumn 37, Issue 1, 2010, Pages 109-112

  Rahman, Nasir ^a   Jafary, Fahim H ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Acute coronary syndromes; Glycoprotein IIb IIIa inhibitors; Percutaneous coronary intervention; Thrombocytopenia; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PACLITAXEL; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART CATHETERIZATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LABORATORY TEST; MALE; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 77950408292     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Aster RH, Curtis BR, Bougie DW, Dunkley S, Greinacher A, Warkentin TE, et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 2006;4(3):678-9.
2. Billheimer JT, Dicker IB, Wynn R, Bradley JD, Cromley DA, Godonis HE, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002;99(10): 3540-6.
3. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005;127(2 Suppl):53S-59S.
4. Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, King SB 3rd. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1998;32(1):28-34.
5. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338(21):1498-505.
6. Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006;97(3):426-9.
7. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators [published erratum appears in N Engl J Med 1998;339(6):415]. N Engl J Med 1998;338(21):1488-97.
8. ReoPro prescribing information [updated 2005 Nov 16; cited 2009 Nov 19]. Available from: http://www.reopro.com/index.htm.
9. Integrilin product information [updated 2009 Jan; cited 2009 Nov 19]. Available from: http://www.spfiles.com/piintegrilin.pdf.
10. Aggrastat prescribing information [updated 2003 May 14; cited 2009 Nov 19]. Available from: http://www.aggrastat.com.sa/secure/resources/pi/pi.html.
11. Brown DL. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 2003;89(5):535-7.
12. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104 (8):870-5.
13. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100(6): 2071-6.
14. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999;138(4 Pt 2):317-26.
15. Clofent-Sanchez G, Harizi H, Nurden A, Coste P, Jais C, Nurden P. A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G. J Thromb Haemost 2007;5(5):1068-70.
16. Demirkan B, Guray Y, Guray U, Korkmaz S. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report. J Thromb Thrombolysis 2006; 22(1):77-8.
17. Eryonucu B, Tuncer M, Erkoc R. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Cardiovasc Drugs Ther 2004;18(6):503-5.
18. Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet 2002;41(3):187-95.
19. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109 (18):2203-6.
20. Castelli R, Cassinerio E, Cappellini MD, Porro F, Graziadei G, Fabris F. Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects. Cardiovasc Hematol Disord Drug Targets 2007;7(3):153-62.